duloxetine / Generic mfg. - LARVOL DELTA

Clinical outcomes in patients with multiple myeloma and antidepressant use: A retrospective cohort study (ASH 2025) - "Adult patients with multiple myeloma since 2010 and prescribed antidepressants (sertraline, escitalopram, citalopram, paroxetine, fluoxetine, fluvoxamine, venlafaxine, duloxetine, trazodone, mirtazapine, or bupropion) were identified using ICD-10 diagnostic and RxNorm codes. While some associations were modest in magnitude, the consistent pattern of increased risk suggests that pre-existing depression and its treatment may identify a more vulnerable subgroup of multiple myeloma patients. Further prospective studies are needed to clarify underlying mechanisms and to evaluate the potential impact of early psychiatric intervention."

Clinical data • Retrospective data • Chronic Kidney Disease • CNS Disorders • Depression • Hematological Malignancies • Infectious Disease • Major Depressive Disorder • Multiple Myeloma • Musculoskeletal Diseases • Nephrology • Renal Disease

Pericapsular nerve block and ablation as a novel pain modifying strategy in sickle cell patients wiht refractory hip pain due to avascular necrosis (ASH 2025) - "Beyond duloxetine, aserotonin and norepinephrine reuptake inhibitor (Brandow et al, Blood Adv, 2020), there is little progresson pain management for medication-resistant pain (Okpala et al, J R Soc Med, 2002)...Under ultrasound guidance, the iliopubiceminence was identified and a solution of 0.25% ropivacaine and 40mg of Kenalog was injected at thetarget area using a 25-gauge needle... A two-step approach to mitigating AVN-associated pain can provide sustained pain relief inpatients with sickle cell disease. Specifically, cryoablation offers nerve-sparing sustained pain relief forpatients who are not surgical candidates. Further work is needed to establish AVN-grade specifictreatment approaches for this patient population."

Clinical • Anesthesia • Genetic Disorders • Hematological Disorders • Immunology • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Pain • Sickle Cell Disease

Duloxetine-induced inhibition of voltage-gated K+ 3.1 (Kv3.1) channels and underlying electrophysiological mechanisms. (PubMed, Toxicol Appl Pharmacol) - "Furthermore, duloxetine inhibited Kv3.1-mediated currents in SH-SY5Y human neuroblastoma cells. Taken together, our results indicate that duloxetine inhibits Kv3.1 expressed in CHO cells in concentration-, time-, and use (open and inactivated states)-dependent manners, independently of its anti-depressive effects."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Neuroblastoma • Oncology • Psychiatry • Solid Tumor

Management of Small Fiber Neuropathy: A Clinical Perspective. (PubMed, Muscle Nerve) - "First-line medications include amitriptyline, nortriptyline, gabapentin, and pregabalin. Second-line treatments can include serotonin-norepinephrine reuptake inhibitors and selective serotonin reuptake inhibitors such as duloxetine and venlafaxine, as well as lidocaine patches and capsaicin."

Journal • Diabetes • Immunology • Infectious Disease • Metabolic Disorders • Neuralgia • Pain

Comparative Cardiovascular Safety of Duloxetine and Gabapentin in Patients with Hip Osteoarthritis. (PubMed, J Pain Res) - "Duloxetine was generally associated with increased CV risks, while a lower risk of AMI and no significant increase in mortality were observed compared to gabapentin. Our subgroup analysis further suggests that when potential confounding from preexisting CVDs was minimized, duloxetine was associated with incident CV complications in patients without prior CVDs."

Journal • Cardiovascular • Cerebral Hemorrhage • Congestive Heart Failure • Heart Failure • Hematological Disorders • Immunology • Ischemic stroke • Musculoskeletal Pain • Myocardial Infarction • Osteoarthritis • Pain • Rheumatology

Dramatic Response to Lidocaine Infusion Therapy for Chronic Generalized Pain Secondary to Multiple Large Keloids. (PubMed, Cureus) - "Conventional treatments, including surgical excision with intralesional corticosteroids, duloxetine, meloxicam, amitriptyline, and acupuncture, provided only transient relief. Moderate pain relief was achieved with pregabalin, nortriptyline, topical lidocaine, and medical marijuana, resulting in a visual analog scale (VAS) score of 8/10. The subsequent addition of intravenous (IV) lidocaine infusions (5 mg/kg administered over one hour) produced significant pain reduction (VAS 3/10) and notable improvements in quality of life and functional capacity, enabling her to maintain employment. The interval between infusions was later extended to every four months while maintaining pain relief, without neuroexcitatory or cardiac complications. This case suggests that periodic IV lidocaine infusions may offer a safe and effective therapeutic option for sustained analgesia in patients with chronic keloid-related pain."

Journal • Fibrosis • Infectious Disease • Mood Disorders • Musculoskeletal Pain • Neuralgia • Pain • Varicella Zoster

Adjustment for dispensed doses does not explain higher antidepressant concentrations in post-mortem toxicology. (PubMed, Br J Clin Pharmacol) - "Dose adjustment generally did not improve the separation of poisoning vs non-poisoning suicides, indicating that post-mortem concentrations may not have clear dose-concentration relationships."

Journal

Patients on Regular Preoperative Weak Opioid Intake Can Achieve Successful Surgical Outcomes After Posterior Decompression Surgery for Cervical Spondylotic Myelopathy. (PubMed, Clin Spine Surg) - "Patients receiving regular weak opioids preoperatively can achieve successful surgical outcomes after posterior decompression surgery for cervical spondylotic myelopathy."

Journal • CNS Disorders • Musculoskeletal Pain • Orthopedics • Pain

Hyperfiltration and Metabolism Before and After a Low-Calorie, Pre-Gastric Bypass Surgery Diet: Significance for Concentrations of Hydrophilic and Lipophilic Drugs. (PubMed, Basic Clin Pharmacol Toxicol) - "The greater the individual weight loss, the greater the concentration increase in hydrophilic drugs that undergo glomerular filtration, for example, pregabalin and gabapentin, suggesting that this reflects decreased glomerular hyperfiltration. By contrast, for highly lipophilic drugs, for example, mirtazapine and sertraline, the greater the individual creatinine and cystatin C loss, the greater the decrease in drug concentration, interpreted as increased drug metabolism based on decreased liver inflammation and steatosis. Venlafaxine/O-desmethylvenlafaxine displayed a complicated pattern suggesting the involvement of both glomerular filtration and metabolism. Serum concentrations of modestly lipophilic drugs, for example, duloxetine and (es)citalopram, were not significantly affected by the diet. In conclusion, hydrophilicity- and lipophilicity-related changes in drug concentrations over the diet period covary with markers of changes in hyperfiltration and metabolism,..."

Journal • Genetic Disorders • Inflammation • CST3

Use of oral neuromodulators in chronic pelvic painNumber 8 - 2025. (PubMed, Rev Bras Ginecol Obstet) - "•Pregabalin is the medication with the best pharmacokinetic profile; nortriptyline has the best adverse effects profile; duloxetine is the most widely used and has the lowest risks; and venlafaxine should be used as a second-line inhibitor. •Although the drug classes can be combined to reduce the total doses and minimize side effects, maximizing the analgesic effect, monotherapies are recommended as the first line to avoid polypharmacy."

Journal • Review • Gynecology • Musculoskeletal Pain • Neuralgia • Pain

Efficacy of Duloxetine in Conjunction With Tramadol for Chronic Cancer Pain (clinicaltrials.gov) - P=N/A | N=400 | Completed | Sponsor: Assiut University | Recruiting ➔ Completed

Trial completion • Oncology • Pain

Duloxetine for LBP (clinicaltrials.gov) - P4 | N=120 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: May 2026 ➔ May 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Therapeutic challenges in a rare trigeminal autonomic cephalalgia (EHF-EHC 2025) - "A discrete improvement was noted with intravenous eptinezumab 300 mg every 12 weeks, in combination with duloxetine, gabapentin, topiramate and tapentadol. He makes excessive use of fast-acting tramadol and ibuprofen to alleviate acute pain...SUNCT remains a therapeutic challenge due to its rarity, limited evidence base, and frequent refractoriness. This reinforces the need for further research and therapeutic innovation."

Rheumatology

Evaluating the efficacy of combined treatment in patients with Persistent Idiopathic Facial Pain (PIFP) (EHF-EHC 2025) - "All patients received combinations of medications targeting neuropathic pain and musculoskeletal tension, antidepressants (e.g., duloxetine, venlafaxine), anticonvulsants (e.g., carbamazepine, gabapentin) and COX-2 inhibitors. Treatment response often required dose titration. Combined pharmacological approaches targetting both neuropathic and affective components may provide meaningful symptom control in PIFP."

Clinical • CNS Disorders • Dental Disorders • Epilepsy • Migraine • Musculoskeletal Diseases • Musculoskeletal Pain • Neuralgia • Novel Coronavirus Disease • Pain

Treatment with gabapentin associated with improved survival in elderly glioblastoma patients (SNO 2025) - "Of these, 797 (32%) received temozolomide alone (TMZ), 147 (5.9%) received gabapentin and temozolomide (TMZ+G), 38 (1.5%) received duloxetine and temozolomide (TMZ+D), and 1,514 (60.8%) received levetiracetam and temozolomide (TMZ+L). In TMZ+G, Women had a 55% decrease in hazard of death (HR=0.45, 95%CI=0.34-0.60, p<0.001) compared to 47% in men (HR=0.63, 95%CI=0.46-0.83) as compared to TMZ. These results show survival benefit associated with gabapentin use, and supports ongoing work suggesting that neuron-glioma interactions represent important therapeutic targets."

Clinical • Brain Cancer • Glioblastoma • Glioma • Solid Tumor

Clinical characterisation and treatment patterns in tension-type headache: A retrospective study from a public hospital cohort (EHF-EHC 2025) - "The most prescribed preventives were amitriptyline, duloxetine, and venlafaxine. Identifying these patterns may help optimise individualised and multidisciplinary treatment approaches. The small and selected cohort, limited to a tertiary care setting, restricts generalisability and further correlation."

Retrospective data • CNS Disorders • Depression • Fibromyalgia • Migraine • Mood Disorders • Musculoskeletal Pain • Pain • Rheumatology

NH102-21: A Phase II Study to Evaluate NH102 for Depression (clinicaltrials.gov) - P2 | N=243 | Completed | Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Mar 2026 ➔ Sep 2025 | Trial primary completion date: Dec 2025 ➔ Jul 2025

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Evaluation of a Second-line Treatment in Female Adolescents With SSRI-nonresponsive Major Depression: A Real-world Data Analysis on Bupropion Versus Duloxetine. (PubMed, J Psychiatr Pract) - "This study is distinct in its focus on female adolescents with MDD, applying a triple-blind design and utilizing both standardized (MADRS) and personalized (GAS-D) outcome measures. By including an analysis of suicide attempt rates, it offers important clinical insights into the comparative effectiveness and safety of bupropion and duloxetine in a particularly vulnerable population."

Clinical • Journal • Real-world evidence • Retrospective data • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry • Suicidal Ideation

Power Spectral Slope as a Novel Brain Functional Marker for Major Depressive Disorder. (PubMed, Biol Psychiatry Glob Open Sci) - "A subset of 52 patients with MDD also underwent rs-fMRI scanning after a 12-week antidepressant treatment (escitalopram/duloxetine). The normalization effect of ventral striatum spectral slope following antidepressant treatment suggests a region-specific response. Taken together, the findings suggest that PSS may serve as a novel brain functional marker for MDD."

Journal • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Cannabidiol induces antiallodinic and antihiperalgesic effects via D2-NFKB dopamine receptor in hemiparkinsonian male rats (Neuroscience 2025) - "Most patients with Parkinson's disease have neuropathic pain and do not receive adequate treatment or do not respond to treatment, even though there are various first-line treatments, such as tricyclic antidepressants, gabapentin, pregabalin, duloxetine and fluoxetine. There are alternative treatments such as lidocaine or capsaicin patches, opioids, and cannabis...On the other hand, we find a decrease in NFKB immunoreactivity and cytokines production. These results show that CBD has analgesic activity and exerts it effect by D2DR via NFKB in 6-OHDA-lesion male rats."

Preclinical • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Neuralgia • Parkinson's Disease • Psychiatry • Schizophrenia • DRD2

Occam's Razor or Hickam's Dictum: Delayed Onset of Pembrolizumab-Induced Podocytopathy and Acute Interstitial Nephritis After Cessation of the Drug (KIDNEY WEEK 2025) - "Medications included levothyroxine, duloxetine, and rifaximin. Our patient showed favorable response to prednisone, with marked improvement in both proteinuria and acute kidney injury (AKI). Continued vigilance for AKI and proteinuria is required even after the ICI is stopped."

Acute Kidney Injury • Glomerulonephritis • Nephrology • Renal Disease • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Unknown Primary

Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder (clinicaltrials.gov) - P3 | N=392 | Completed | Sponsor: Zhejiang Huahai Pharmaceutical Co., Ltd.

New P3 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Chronic Pain in the Cancer Survivor. (PubMed, Curr Pain Headache Rep) - "Evidence supports the use of duloxetine for chemotherapy-induced peripheral neuropathy...A personalized and multimodal approach is recommended for chronic pain in cancer survivors. Further investigations into the treatment for chronic pain syndromes in cancer survivors are critical to improve the long-term outcomes and quality of life for cancer survivors."

Journal • Review • Musculoskeletal Pain • Oncology • Pain • Peripheral Neuropathic Pain

Comparative gastrointestinal effects of antidepressants for the acute treatment of adults with major depressive disorder: a network and dose‒response meta-analysis. (PubMed, Transl Psychiatry) - "Commonly used antidepressants have different gastrointestinal effects. Duloxetine, levomilnacipran, and vilazodone carry a higher risk of inducing nausea and vomiting, whereas trazodone, amitriptyline, agomelatine, and mirtazapine tend to be better tolerated. Amitriptyline, clomipramine, and reboxetine are more prone to induce constipation. Diarrhoea is more commonly associated with vilazodone, fluvoxamine, and sertraline. Amitriptyline, reboxetine, and duloxetine are more likely to cause anorexia. Amitriptyline, reboxetine, and trazodone are related to causing dry mouth. Compared with the placebo, amitriptyline, fluoxetine, and paroxetine were associated with a greater incidence of dyspepsia."

Journal • Retrospective data • Review • Anorexia • CNS Disorders • Constipation • Depression • Dyspepsia • Gastroenterology • Gastrointestinal Disorder • Major Depressive Disorder • Mood Disorders • Psychiatry • Xerostomia

Anti-prion drugs reduce endoplasmic reticulum stress and protect human dopaminergic neurons from death. (PubMed, Biomed Pharmacother) - "Notably, several compounds - benzydamine, duloxetine, flunarizine, metixene and triflupromazine - protected LUHMES cells from MPP+ -induced ER stress at nanomolar concentrations. These findings provide the proof of concept that drugs selected for other indications, may be repurposed to ameliorate PD and related pathologies linked to ER stress."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease